

Laurie Elit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1683278/publications.pdf>

Version: 2024-02-01

32
papers

361
citations

933447

10
h-index

839539

18
g-index

33
all docs

33
docs citations

33
times ranked

616
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. <i>Current Oncology</i> , 2022, 29, 231-242.	2.2	3
2	Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study. <i>Cancer Biomarkers</i> , 2022, 34, 347-358.	1.7	4
3	Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II–IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103324.	4.4	6
4	Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103336.	4.4	3
5	Comparison of Alinity m HPV and cobas HPV assays on cervical specimens in diverse storage media. <i>Tumour Virus Research</i> , 2021, 12, 200224.	3.8	1
6	How to reduce the impact of cervical cancer worldwide: Gaps and priority areas identified through the essential cancer and primary care packages: An analysis of effective interventions. <i>Cancer</i> , 2020, 126, 4697-4705.	4.1	6
7	CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2020, 10, 100206.	4.5	7
8	Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. <i>Gynecologic Oncology</i> , 2020, 157, 36-45.	1.4	9
9	Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports. <i>ESMO Open</i> , 2020, 5, e000878.	4.5	5
10	Treatment of first-void urine with Aptima Transfer Solution increases detection of high-risk HPV E6/E7 mRNA. <i>Journal of Virological Methods</i> , 2019, 267, 48-52.	2.1	8
11	Care Delivery Patterns, Processes, and Outcomes for Primary Ovarian Cancer Surgery: A Population-Based Review Using a National Administrative Database. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 25-33.	0.7	12
12	Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 155-159.	4.5	3
13	Does a groin node dissection in vulvar cancer affect groin recurrence and overall survival?: Results from a population-based cohort study. <i>Gynecologic Oncology</i> , 2017, 144, 318-323.	1.4	4
14	Cervical Cancer Screening in Low-Resource Settings. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 1183-1184.	0.7	0
15	Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 478-478.	1.6	0
16	Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example. <i>Journal of Market Access & Health Policy</i> , 2016, 4, 31463.	1.5	1
17	Comparing stage of diagnosis of cervical cancer at presentation in immigrant women and long-term residents of Ontario: a retrospective cohort study. <i>CMAJ Open</i> , 2016, 4, E424-E430.	2.4	12
18	Recommendations for Follow-up Care for Gynecologic Cancer Survivors. <i>Obstetrics and Gynecology</i> , 2015, 126, 1207-1214.	2.4	21

#	ARTICLE	IF	CITATIONS
19	Further Insights Into Long-Term Trends in Relative Survival of Vulvar Cancer Patients: A Population-Based Study. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 125-130.	2.5	5
20	Wait times from diagnosis to treatment in cancer. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 246.	2.2	8
21	Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: A population-based cohort study. <i>Gynecologic Oncology</i> , 2015, 139, 465-470.	1.4	5
22	Role of cervical screening in older women. <i>Maturitas</i> , 2014, 79, 413-420.	2.4	21
23	The association between cervical cancer screening and mortality from cervical cancer: A population based case-control study. <i>Gynecologic Oncology</i> , 2014, 133, 167-171.	1.4	38
24	Cervical cancer in the older woman. <i>Maturitas</i> , 2014, 78, 160-167.	2.4	20
25	Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: A population-based study. <i>Gynecologic Oncology</i> , 2014, 134, 314-318.	1.4	70
26	Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. <i>OncoTargets and Therapy</i> , 2013, 6, 107.	2.0	25
27	Walking a tightrope: oncologists' perspective on providing information to women with recurrent ovarian cancer (ROC) during the medical encounter. <i>Supportive Care in Cancer</i> , 2012, 20, 2327-2333.	2.2	9
28	Sociodemographic factors associated with cervical cancer screening and follow-up of abnormal results. <i>Canadian Family Physician</i> , 2012, 58, e22-31.	0.4	27
29	Management of Women with Surgically Staged 1 Uterine Papillary Serous Cancer. <i>ISRN Obstetrics & Gynecology</i> , 2011, 2011, 1-9.	1.2	2
30	Who are the Providers of Gynaecologic Cancer Surgical Care in Ontario?. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2009, 31, 721-729.	0.7	0
31	The Quality of the Operative Report for Women With Ovarian Cancer in Ontario. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2006, 28, 892-897.	0.7	16
32	Management of Colposcopy Patients with Biopsy-Proven Cervical Intraepithelial Neoplasia Grade 1. <i>Journal of Lower Genital Tract Disease</i> , 1999, 3, 191-195.	1.9	9